Hepatitis C Virus NS5A Inhibitor
8 drugs across 4 manufacturers|1 Generic,7 Brand
The Hepatitis C Virus NS5A Inhibitor class contains 8 NDCs from 4 manufacturers (1 generic, 7 brand), at an average NADAC of $524.39 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
8
1G / 7B
Manufacturers
4
Avg $524.3854/unit
Avg 7d Change
-0.02%
Across 5 drugs with changes
7d Activity
of 8 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Manufacturer Breakdown
4 manufacturers producing drugs in this therapeutic class
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
HARVONI 90-400 MG TABLET LEDIPASVIR and SOFOSBUVIR | $1098.9375 per EA | — |
EPCLUSA 400 MG-100 MG TABLET Velpatasvir and Sofosbuvir | $866.3988 per EA | +0.05% |
VOSEVI 400-100-100 MG TABLET SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR | $858.6884 per EA | — |
ZEPATIER 50-100 MG TABLET elbasvir and grazoprevir | $634.2375 per EA | — |
SOFOSBUVIR-VELPATASVIR 400-100 Velpatasvir and Sofosbuvir | $278.0492 per EA | -0.04% |
MAVYRET 100-40 MG TABLET Glecaprevir and Pibrentasvir | $152.9239 per EA | -0.07% |
MAVYRET 100-40 MG TABLET Glecaprevir and Pibrentasvir | $152.9239 per EA | -0.07% |
MAVYRET 100-40 MG TABLET Glecaprevir and Pibrentasvir | $152.9239 per EA | -0.07% |
Frequently Asked Questions
How many drugs are in the Hepatitis C Virus NS5A Inhibitor class?
The Hepatitis C Virus NS5A Inhibitor class contains 8 NDCs from 4 manufacturers — 1 generic and 7 brand products.
What is the average price of Hepatitis C Virus NS5A Inhibitor drugs?
The average NADAC for the Hepatitis C Virus NS5A Inhibitor class is $524.3854 per unit across 8 NDCs.
Is generic cheaper than brand in the Hepatitis C Virus NS5A Inhibitor class?
Among products priced per EA, the average generic NADAC in this class is $278.0492, versus $559.5763 for brand — brand products average about 2.0× the generic price.
Which manufacturers make Hepatitis C Virus NS5A Inhibitor drugs?
4 manufacturers make drugs in the Hepatitis C Virus NS5A Inhibitor class. Ranked by number of NDCs, the largest are Gilead Sciences, Inc. (3), AbbVie Inc. (3), Merck Sharp & Dohme LLC (1), Asegua Therapeutics LLC (1).
How has Hepatitis C Virus NS5A Inhibitor pricing changed recently?
Over the past 7 days, 1 NDC in this class rose and 4 fell, with a class-wide average change of -0.0%.